NCT03931135

Brief Summary

Comparing between cyclizine and dexamethasone in preventing PONV after CS under spinal anesthesia with spinal opiate.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2019

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 26, 2019

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 30, 2019

Completed
4 months until next milestone

Study Start

First participant enrolled

September 1, 2019

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

April 30, 2019

Status Verified

March 1, 2019

Enrollment Period

1.2 years

First QC Date

March 26, 2019

Last Update Submit

April 25, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Post operative nausea and vomiting after intrathecal morphine by using PONV intensity scale.

    Nausea and vomiting were recorded as present or absent, All measurements and ratings were completed at the time when patients rated their PONV intensity. We also recorded factors known to be associated with the risk of developing PONV, including known risk factors for PONV.

    Change in severity of nausea and vomiting 30 minutes , 3 hours, 6 hours after intervention

Secondary Outcomes (1)

  • Change in postoperative pain (assessed by VAS ).

    Immediatly before and after intervention, 30 minutes after intervention, 3 hours after intervention, 6 hours

Study Arms (2)

Dexamethasone

ACTIVE COMPARATOR
Drug: IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section

Cyclizine

ACTIVE COMPARATOR
Drug: IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section

Interventions

The first group (Dexamethasone) will receive 8 mg IV dexamethasone within 1-2 minutes after the umbilical cord is clamped. The second group (Cyclizine) will receive 50 mg cyclizine within 1-2 minutes after the umbilical cord is clamped

CyclizineDexamethasone

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Female
  • to 45 years old
  • Parturient
  • ASA I-II
  • Full Term

You may not qualify if:

  • Women who has obstetric complications.
  • Women with evidence of foetal compromise.
  • Patients who have gastro-intestinal diseases.
  • Administration of anti-emetic drugs within 24 hours before operation.
  • Patients who have hyperemesis gravidarium

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Mina Habib, Principal Investigator

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 26, 2019

First Posted

April 30, 2019

Study Start

September 1, 2019

Primary Completion

October 31, 2020

Study Completion

December 1, 2020

Last Updated

April 30, 2019

Record last verified: 2019-03